Fermenta Biotech share price today

Fermenta Biotech Ltd's share price was ₹439.80 at the close on 4 November 2026. It has been rising for 17 weeks. That is 7.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹269 and ₹560, and at that close it sat 59% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Fermenta Biotech Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row.

Over the last 11 years the share price moved +628% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: promoters cut their stake by 4 points in one quarter, lowest operating margin in 8 quarters and foreign funds (FIIs) raised their stake for 3 quarters in a row.

1. Promoters cut their stake by 4 points in one quarter

   From 64.1% to 60.1% in the September 2026 quarter.

2. Lowest operating margin in 8 quarters

   Operating margin was 14.8% in the June 2026 quarter, against 20.7% a year earlier.

3. Foreign funds (FIIs) raised their stake for 3 quarters in a row

   From 0% to 1.1% of the company by the September 2026 quarter.

For April to June 2026 (the quarter ended 30 June 2026), Fermenta Biotech reported revenue of ₹122 crore, down 10.6% from ₹136 crore a year earlier, and a profit of ₹9.53 crore, down 55.9% from ₹21.6 crore.

Fermenta Biotech results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Fermenta Biotech closed at ₹439.80 on 4 November 2026, up 57.9% from ₹278.60 a year earlier (7 November 2025) and up 44.1% over five years. Its highest weekly close since March 2016 was ₹559.55 on 7 August 2026.

Fermenta Biotech share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

558 weekly closes from 10 March 2016 to 4 November 2026.

4 Nov 2026: Fermenta Biotech closed at ₹439.80, up 5.3% on the week and down 20.2% on the month. 5 Aug 2026: ex-date for a dividend of ₹3.75 a share.

Earlier

• Results for April to June 2026: Revenue down 10.6% and profit down 55.9% on a year earlier.

Fermenta Biotech paid ₹3.75 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.85% at the ₹439.80 close on 4 November 2026. The last was a dividend of ₹3.75 a share, ex-date 5 August 2026.

Fermenta Biotech dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Fermenta Biotech Ltd paid out 15% of its profit as dividends in FY26, and it paid a dividend in 9 of its last 13 reported years. 4 of those years show a negative figure because profit itself was negative.

From the NSE corporate-actions record, read 5 November 2026.

Fermenta Biotech's management made 0 promises we could check against what it later reported.

Our read after the latest results, written 17 May 2026.

What is changing at Fermenta Biotech, from the latest results and calls: vitamin d3 demand recovery, channel inventory normalisation, plant-based vitamin d3 patent + ₹110 crore capital spending and geographic expansion, 60+ country footprint deepening.

• Vitamin D3 Demand Recovery, Channel Inventory Normalisation. 9M FY26 ex-real-estate operating profit already +14% above full FY25. ⚠ estimate
• Geographic Expansion, 60+ Country Footprint Deepening. Revenue mix well-diversified: India 40%, Europe 27%, North America 17%, Others 16% (FY25). Limited concentration, top customer only 9% of revenue. 400+ customers across 60+ countries. ⚠ estimate
• Green Chemistry / Enzyme Revenue Diversification. Green Chemistry Solutions revenue +64% on a year earlier in 9M FY26; FY25 green chemistry at ₹38 crore vs ₹29 crore in FY24. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the latest results, written 17 May 2026.

October to December 2025 operating margin compressed to 18%, normalised band may be 18-22%, not 25-34%.

The main risks

• Operating margin Cyclicality, FY25 Peak May Not Recur: October to December 2025 operating margin compressed to 18%, normalised band may be 18-22%, not 25-34%. ⚠ estimate
• Real Estate Revenue Non-Recurrence: Real estate segment revenue declined 95% on a year earlier in 9M FY26; FY25 included ₹45 crore real estate. This non-recurring element inflated FY25 profitability and is now absent from FY26. ⚠ estimate
• Institutional Ownership Desert, Low Market Profile: FII at 0.02%, DII at 0%, essentially zero institutional ownership. Stock was BSE-only until NSE permitted to trade admission in Apr 2026. Market discovery dependent on retail interest. ⚠ estimate

Our read after the latest results, written 17 May 2026.

When Fermenta Biotech reports July to September 2026, these are the 5 checks that show whether the story is still on course. First: CARE Ratings annual review / Fermenta realisation per kg D3 in quarterly disclosures.

Fermenta Biotech is on one of our India lists: Pharma stocks.

Fermenta Biotech Ltd earned ₹9.5 Cr of net profit in the Jun 2026 quarter, −55.9% on the same quarter a year earlier. Full-year FY26 profit was ₹70.0 Cr. Over 10 years profit has grown 42.7% a year on average. That is 7.8% of the quarter's revenue. The same quarter a year earlier earned ₹21.6 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

3 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was ₹70.0 Cr (−7.9% on the year before).

Why profit moved: revenue changed −10.6% on a year earlier and the margin moved −5.9 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −26.6% and revenue +0.3%. Profit is growing slower than sales: rising costs are taking part of the growth.

Fermenta Biotech Ltd reported ₹122 Cr of revenue in the Jun 2026 quarter, −10.6% on the same quarter a year earlier. Over 10 years it has grown 12.9% a year on average. The last full year, FY26, came in at ₹523 Cr. The last four reported quarters add to ₹511 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. The company received an Indian Patent for its plant-based Vitamin D3 manufacturing process in September 2025. MD Prashant Nagre stated: 'Plant-based Vitamin D3 represents the future of nutrition, and this patent reinforces our ability to deliver differentiated offerings that create long-lasting impact.' The company has completed validation batches of VITADEE Green (plant-source D3 in oil and spray-dried variants) and is in the qualification process with leading global customers. The global shift away from lanolin-derived cholecalciferol toward vegan alternatives is a structural trend cited by multiple industry reports (Technavio: CAGR 7.1% 2025-2030, with plant-based as a key driver).…

FY26 revenue was ₹523 Cr, +11.8% on the year before.

Recent pace: the last four quarters grew +0.3% on average, against 12.9% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −3.2%, against +24.2% a year over the last 8 quarters (rolling over).

Fermenta Biotech Ltd's operating margin was 14.8% in the Jun 2026 quarter, 5.9 percentage points lower than the same quarter a year ago. Across 13 years it has been between 5.0% and 39.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. Fermenta's FY23 and FY24 losses were directly caused by two factors: (1) channel inventory built during COVID demand spikes took 2 years to normalise, suppressing human nutrition D3 off-take; (2) Chinese capacity expansion compressed animal feed D3 realisations. Both headwinds abated in FY25. The recovery was sharp. CARE Ratings confirmed: 'demand has recovered in FY25 with normalisation of channel inventory in Vitamin D3 products for human consumption, relative stability in realisations in Vitamin D3 products for animal consumption and increased realisation of Vitamin D3 products for human consumption.' 9M FY26 saw Human Nutrition D3 volume +46% YoY and Animal Nutrition +52%. However, Q3…

Why the margin moved: operating margin changed −5.9 percentage points on the year while gross margin changed +3.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 110% of Fermenta Biotech Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹93.0 Cr of operating cash against ₹70.0 Cr of profit. After ₹12.0 Cr of spending on assets, ₹81.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 110% of profit came in as cash: the cash cycle got 117 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: it has been selling more assets than it buys. The next section shows those figures.

Fermenta Biotech Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 221 days in FY26, down from 338 days in FY21. Over the last 3 years it sold more assets than it bought, by ₹8.0 Cr. Customers take 78 days to pay, and stock sits for 290 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹523 Cr, each day of that cycle ties up about ₹1.4 Cr, so roughly ₹317 Cr is tied up in the business at any time.

FY26: customers took 78 days to pay and stock sat for 290 days, about 9.5 months of sales sitting as stock, for a full cycle of 221 days, shorter than FY21's 338.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 290 days. Customers pay about 78 days after that. Suppliers are paid at 147 days. Together that makes the 221-day cycle.

Over the last 3 years, money from selling assets was ₹8.0 Cr more than it spent on new ones. Work still in progress is ₹13.0 Cr (FY26).

In short: assets are being sold, not built, so this cash is not going into new capacity.

Fermenta Biotech Ltd's P/E is 23.6×, near the high end of its own history: higher than 73% of past readings. Its usual P/E (the middle reading) is 17.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹20.28.